Norepinephrine suppresses wound macrophage phagocytic efficiency through alpha- and beta-adrenoreceptor dependent pathways.
BACKGROUND
The systemic response to injury is characterized by massive release of norepinephrine (NE) into the circulation as a result of global sympathetic activation. We have recently demonstrated that NE modulates the recruitment of macrophages to the cutaneous wound. We hypothesized that NE suppresses wound macrophage phagocytic function through canonical adrenergic signaling pathways.


METHODS
Murine wound macrophages were harvested at 5 days after injury and treated with physiologic and pharmacologic dose norepinephrine. Phagocytosis of green fluorescent protein-labeled Escherichia coli was assayed by flow cytometry. The signaling pathways mediating NE modulation of wound macrophage phagocytosis were interrogated by pharmacologic manipulation of alpha- and beta-adrenoreceptors (ARs), intracellular cyclic adenosine monophosphate (cAMP), and protein kinase A (PKA). Tissue specificity was determined by comparison of wound macrophages to splenic macrophages.


RESULTS
Both physiologic and pharmacologic dose NE suppressed wound macrophage phagocytic efficiency. This effect was mediated by alpha- and beta-ARs in a dose-dependent fashion. Direct stimulation of cAMP-suppressed phagocytic efficiency and blockade of PKA signaling prevented NE-mediated suppression of phagocytic efficiency. Splenic macrophage phagocytic efficiency was less than that of wound macrophages and was not altered by NE.


CONCLUSIONS
NE has a profound immunosuppressive effect on wound macrophage function that is tissue specific and appears to be mediated through adrenergic receptors and their canonical downstream signaling pathway. Attenuation of post-injury immunosuppression represents another potential mechanism by which beta-AR blockade may reduce morbidity and mortality after severe injury.
Gosain
Ankush
A
Burn and Shock Trauma Institute, Loyola University Medical Center, Maywood, Ill, USA.
Muthu
Kuzhali
K
Gamelli
Richard L
RL
DiPietro
Luisa A
LA
D000316:Adrenergic alpha-Agonists / Q000276:immunology* / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D002478:Cells, Cultured; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism; D004926:Escherichia coli / Q000276:immunology; D007546:Isoquinolines / Q000494:pharmacology; D008264:Macrophages / Q000276:immunology / Q000378:metabolism* / Q000382:microbiology; D051379:Mice; D009638:Norepinephrine / Q000276:immunology* / Q000378:metabolism / Q000494:pharmacology; D010587:Phagocytosis / Q000187:drug effects / Q000276:immunology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011942:Receptors, Adrenergic, alpha / Q000378:metabolism*; D011943:Receptors, Adrenergic, beta / Q000378:metabolism*; D013154:Spleen / Q000166:cytology / Q000276:immunology; D013449:Sulfonamides / Q000494:pharmacology; D014947:Wounds and Injuries / Q000276:immunology* / Q000378:metabolism
D000316:Adrenergic alpha-Agonists; D007546:Isoquinolines; D047428:Protein Kinase Inhibitors; D011942:Receptors, Adrenergic, alpha; D011943:Receptors, Adrenergic, beta; D013449:Sulfonamides; D005576:Colforsin; D000242:Cyclic AMP; D017868:Cyclic AMP-Dependent Protein Kinases; C063509:N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide; D009638:Norepinephrine
Am J Respir Cell Mol Biol. 1994 May;10(5):565-72
8179921
Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2517-21
7681600
Am J Surg. 1980 Jul;140(1):144-50
7396078
J Intensive Care Med. 2006 May-Jun;21(3):160-72
16672638
Brain Behav Immun. 2002 Feb;16(1):62-73
11846441
J Immunol. 1990 Sep 1;145(5):1430-4
2166759
Am J Surg. 2004 May;187(5A):11S-16S
15147986
Eur J Pharmacol. 1999 Jul 9;376(3):257-64
10448885
Am J Pathol. 1975 Jan;78(1):71-100
1109560
Immunopharmacol Immunotoxicol. 1994 Nov;16(4):611-25
7876464
J Neuroimmunol. 1991 Jan;31(1):35-42
1845768
Wound Repair Regen. 1998 May-Jun;6(3):194-201
9776863
J Interferon Cytokine Res. 2005 Jul;25(7):384-94
16022583
Mol Cell Biochem. 2003 Dec;254(1-2):299-304
14674709
Surg Clin North Am. 1988 Feb;68(1):181-97
3277303
Pharmacol Rev. 2000 Dec;52(4):595-638
11121511
J Immunol. 1985 Aug;135(2):1338-41
2409147
J Immunol. 2004 Jul 1;173(1):559-65
15210817
Wound Repair Regen. 2005 Sep-Oct;13(5):498-505
16176458
Trends Cell Biol. 1995 Mar;5(3):85-7
14732160
J Neuroimmunol. 2000 Feb 1;103(1):34-40
10674987
J Immunol. 2005 Jan 15;174(2):595-9
15634874
Arch Surg. 1992 Aug;127(8):899-903
1642533
J Trauma. 2006 Apr;60(4):736-44
16612292
J Leukoc Biol. 2004 Sep;76(3):509-13
15218057
J Neuroimmunol. 2003 Feb;135(1-2):47-55
12576223
Methods. 2000 Jul;21(3):203-20
10873475
Immunity. 2003 Jul;19(1):71-82
12871640
Proc Soc Exp Biol Med. 1964 Nov;117:373-6
14233445
Gen Comp Endocrinol. 2004 Apr;136(2):180-91
15028521
J Immunol. 1998 Apr 1;160(7):3562-8
9531319
Curr Opin Immunol. 2002 Feb;14(1):136-45
11790544
Surg Clin North Am. 1997 Jun;77(3):637-50
9194884
J Invest Dermatol. 2001 Nov;117(5):1027-35
11710909
J Neuroimmunol. 2005 Jan;158(1-2):50-7
15589037
J Immunol. 1994 Mar 15;152(6):3024-31
8144901
Annu Rev Immunol. 1984;2:283-318
6100475
J Exp Med. 1992 Jul 1;176(1):287-92
1613462
Science. 1997 Apr 4;276(5309):75-81
9082989
J Neuroimmunol. 1995 Sep;61(2):123-31
7593548